If you are experiencing problems downloading PDF or HTML fulltext, our helpdesk recommend clearing your browser cache and trying again. If you need help in clearing your cache, please click here . Still need help? Email help@ingentaconnect.com

Successful tocilizumab treatment in a patient with human herpesvirus 8‐positive and human immunodeficiency virus‐negative multicentric Castleman's disease of plasma cell type nonresponsive to rituximab‐CVP therapy

$48.00 plus tax (Refund Policy)

Download / Buy Article:

Abstract:

We present and discuss the case of a HIV‐negative female finally diagnosed upon histopathologic and molecular biologic evaluations with human herpesvirus 8 (HHV8)‐positive multicentric Castleman's disease (MCD) of plasma cell type, but with no detectable HHV8‐DNA in peripheral blood. She failed to respond to combination immunosuppressive therapeutic trials of corticosteroids and azathioprine, and neither an immunochemotherapy of rituximab‐CVP (R‐CVP) induced disease resolution. However, monoclonal anti‐IL‐6R antibody (tocilizumab) immunotherapy resulted in beneficial disease stabilization. A control lymph node biopsy indicated mild polyclonal plasmacytosis, and a negative HHV8 determination. The patient is still receiving tocilizumab. This case emphasizes the individual nature of MCD requiering more personalized disease management.

Document Type: Research Article

DOI: http://dx.doi.org/10.1111/apm.12029

Publication date: July 1, 2013

Related content

Tools

Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more